<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Neoadjuvant FOLFIRINOX in patients with locally advanced unresectable or borderline resectable pancreatic cancer</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Neoadjuvant FOLFIRINOX in patients with locally advanced unresectable or borderline resectable pancreatic cancer</h1>
<div class="graphic"><div class="figure"><div class="ttl">Neoadjuvant FOLFIRINOX in patients with locally advanced unresectable or borderline resectable pancreatic cancer</div><div class="cntnt"><table cellspacing="0"><colgroup span="7" width="14%"></colgroup> <tbody> <tr> <td class="subtitle1">Authors, year</td> <td class="subtitle1">Number of patients</td> <td class="subtitle1">Regimen</td> <td class="subtitle1">Radiographic response rate</td> <td class="subtitle1">Number of patients with subsequent resection</td> <td class="subtitle1">R0 resections</td> <td class="subtitle1">Median survival for resected patients (months)</td> </tr> <tr> <td>Conroy T, 2005</td> <td>11</td> <td>FOLFIRINOX</td> <td>3 of 11 (27%)</td> <td>0</td> <td>0</td> <td>–</td> </tr> <tr> <td>Peddi PF, 2012</td> <td>19</td> <td>FOLFIRINOX then RT (n = 4)</td> <td>6 of 18* (33%)</td> <td>8 of 23 (35%)</td> <td>Not reported</td> <td>Not reported</td> </tr> <tr> <td>Vasile E, 2012</td> <td>15</td> <td>FOLFIRINOX then CRT (n = 3)</td> <td>6 of 15 (40%)</td> <td>5 (33%)</td> <td>–</td> <td>30.1 (all 15 patients)</td> </tr> <tr> <td>Mahaseth H, 2013</td> <td>24</td> <td>FOLFIRINOX then CRT (n = 14)</td> <td>Not stated</td> <td>6 (25%)</td> <td>Not reported</td> <td>Not reported</td> </tr> <tr> <td>Hosein PJ, 2013<sup>¶</sup></td> <td>18</td> <td>FOLFIRINOX then CRT (n = 10)</td> <td>Not stated</td> <td>6 after CT, 3 after CRT (50%)</td> <td>8 of 9 (89%)</td> <td>Not reported</td> </tr> <tr> <td>Boone BA, 2013</td> <td>13</td> <td>FOLFIRINOX then SBRT (n = 5)</td> <td>Not stated</td> <td>2 (15%)</td> <td>1 of 2 (50%)</td> <td>Not reported</td> </tr> <tr> <td>Christians KK, 2014<sup>¶</sup></td> <td>18</td> <td>FOLFIRINOX then CRT</td> <td>Not stated</td> <td>12 (67%)</td> <td>12 of 12 (100%)</td> <td>7 of 12 alive at median 22 months after diagnosis</td> </tr> <tr> <td>Marthey L, 2015</td> <td>77</td> <td>FOLFIRINOX then RT (n = 24)</td> <td>22 of 77 (28%)</td> <td>28 (36%)</td> <td>25 of 28 (89%)</td> <td>24.9</td> </tr> <tr> <td>Ferrone CR, 2015</td> <td>40</td> <td>FOLFIRINOX then CRT (n = 24)</td> <td>36 of 40 (90%)</td> <td>40 (100%)</td> <td>37 (92%)</td> <td>Approximately 32</td> </tr> <tr> <td>Blazer M, 2015</td> <td>43</td> <td>FOLFIRINOX then CRT (n = 23)</td> <td>9 of 40 (23%)<sup>Δ</sup></td> <td>22 (51%)</td> <td>19 (86%)</td> <td>34.0</td> </tr> <tr> <td>Mellon EA, 2015<sup>◊</sup></td> <td>159</td> <td>FOLFIRINOX (n = 23), GTX (n = 94), Gem (n = 28), or Gem/Abrax (n = 8), then SBRT</td> <td>Not stated</td> <td>61 (38%)</td> <td>59 (96%)</td> <td>34.2</td> </tr> <tr> <td>Sadot E, 2015</td> <td>101</td> <td>FOLFIRINOX then CRT (n = 63)</td> <td>(29%)</td> <td>31 (31%)</td> <td>16 of 31 (55%)</td> <td>Not yet reached(median follow-up 12 months)</td> </tr> <tr> <td>Stein SM, 2016</td> <td>31</td> <td>FOLFIRINOX</td> <td>5 of 29 (17%)</td> <td>13 (42%)</td> <td>13 of 13 (100%)</td> <td>Not reported</td> </tr> <tr> <td>Kim SS, 2016</td> <td>26</td> <td>FOLFIRINOX then RT (n = 4)</td> <td>13 of 26 (50%)</td> <td>26 of 26 (100%)</td> <td>24 of 26 (92%)</td> <td>Not yet reached (median follow-up 27.6 months)</td> </tr> <tr> <td>Katz MH, 2016</td> <td>22</td> <td>FOLFIRINOX then CRT</td> <td>6 of 22 (27%)</td> <td>15 (68%)</td> <td>14 of 15 (93%)</td> <td>Median 21.7</td> </tr> <tr> <td>Murphy JE, 2018</td> <td>48</td> <td>FOLFIRINOX then short-course CRT (n = 27) or long-course CRT (n = 17)</td> <td>19 of 48 (44%)</td> <td>32 (65%)</td> <td>31 of 32 (97%)</td> <td>Two-year overall survival 72%</td> </tr> </tbody></table></div><div class="graphic_footnotes">FOLFIRINOX: short-term infusional fluorouracil plus leucovorin, irinotecan, and oxaliplatin; R0: microscopically complete; RT: radiation therapy; CRT: chemoradiotherapy; CT: computed tomography; SBRT: stereotactic body radiation therapy; GTX: gemcitabine plus docetaxel plus capecitabine; Gem: gemcitabine; Gem/Abrax: gemcitabine/nanoparticle albumin-bound placitaxel.<br/>* The 19<sup>th</sup> patient did not have imaging available after three cycles of chemotherapy.<br/>¶ These series include patients treated with FOLFIRINOX for both unresectable or borderline resectable locally advanced pancreatic carcinoma.<br/>Δ Three patients died before restaging scans were completed.<br/><font class="lozenge">◊</font> Data not reported separately for each neoadjuvant chemotherapy regimen. However, of the 49 patients with locally advanced pancreatic cancer, 5 responded sufficiently on imaging to undergo R0 resection after neoadjuvant therapy. All received FOLIRINOX.</div><div class="graphic_reference">Data from: 

<ol>
<li>Conroy T, Paillot B, François E, et al. Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer – a Groupe Tumeurs Digestives of the Fédération Nationale des Centres de Lutte Contre le Cancer study. J Clin Oncol 2005; 23:1228.</li>
<li>Peddi PF, Lubner S, McWilliams R, et al. Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma. JOP 2012; 13:497.</li>
<li>Vasile E, De Lio N, Cappelli C, et al. Neoadjuvant modified FOLFOXIRI in locally advanced pancreatic cancer. Ann Oncol 2012; 23 Suppl 9:ix241. Abstr 726P.</li>
<li>Mahaseth H, Brutcher E, Kauh J, et al. Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma. Pancreas 2013; 42:1311.</li>
<li>Hosein PJ, Macintyre J, Kawamura C, et al. A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline resectable locally advanced pancreatic adenocarcinoma. BMC Cancer 2012; 12:199.</li>
<li>Boone BA, Steve J, Krasinskas AM, et al. Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer. J Surg Oncol 2013; 108:236.</li>
<li>Christians KK, Tsai S, Mahmoud A, et al. Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm? Oncologist 2014; 19:266.</li>
<li>Marthey L, Sa-Cunha A, Blanc JF, et al. FOLFIRINOX for locally advanced pancreatic adenocarcinoma. Results of an AGEO multicentric prospective observational cohort. Ann Oncol 2015; 22:295.</li>
<li>Ferrone CR, Marchegiani G, Hong TS, et al. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg 2015; 261:12.</li>
<li>Blazer M, Wu C, Goldberg RM, et al. Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas. Ann Surg Oncol 2015; 22:1153.</li>
<li>Mellon EA, Hoffe SE, Springett GM, et al. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma. Acta Oncol 2015; 54:979.</li>
<li>Sadot E, Doussot A, O'Reilly EM, et al. FOLFIRINOX induction therapy for stage 3 pancreatic adenocarcinoma. Ann Surg Oncol 2015; 22:3512.</li>
<li>Stein SM, James ES, Deng Y, et al. Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer. Br J Cancer 2016; 114:737.</li>
<li>Kim SS, Nakakura EK, Wang ZJ, et al. Preoperative FOLFIRINOX for borderline resectable pancreatic cancer: Is radiation necessary in the modern era of chemotherapy? J Surg Oncol 2016; 114:587</li>
<li>Katz MH, Shi Q, Ahmad SA, et al. Preoperative modified FOLFIRINOX treatment followed by capecitabine-based chemoradiation for borderline resectable pancreatic cancer: Alliance for Clinical Trials in Oncology Trial A021101. JAMA Surg 2016; 151:e161137.</li>
<li>Murphy JE, Wo JY, Ryan DP, et al. Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial. JAMA Oncol 2018; 4:963.</li></ol></div><div id="graphicVersion">Graphic 101296 Version 8.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
